OPDIVO® (Nivolumab) plus YERVOY® (Ipilimumab)

The FDA on May 26, 2020 approved the combination of OPDIVO® plus YERVOY® and 2 cycles of Platinum-doublet chemotherapy, as first-line treatment for patients with metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC), with no Epidermal Growth Factor Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) genomic tumor aberrations. OPDIVO® and YERVOY® are products of Bristol-Myers Squibb Co.